The legal battle between Bristol-Myers Squibb Co. and Nanocopoeia, LLC continues to garner industry attention.
The case is formally known as Bristol-Myers Squibb Co. v. Nanocopoeia, LLC, No. 22-cv-1283, 2023 WL 2867945 (D. Minn. Apr. 10, 2023) (Menendez, J.).
This dispute involves the drug product Sprycel® (dasatinib) and two relevant U.S. patents – Nos. 7,491,725 (“the ’725 patent”) and 8,680,103 (“the ’103 patent”).
Nanocopoeia, a nano-drug company, and Bristol-Myers Squibb, an American multinational biopharmaceutical corporation, bring years of experience and research to the courtroom. The result of this case could potentially have considerable ramifications, impacting not only the future of these organizations but also the biomedical and pharmaceutical industries.
Further information and updates regarding this ongoing case can be found in an article written by Robins Kaplan LLP, a national trial law firm.